H

appy new year and welcome back from the holidays. It’s going to be an exciting year, but let’s take it one week at a time. Here’s what we’re looking for this week:

The (possible) conclusion of a biotech saga

Biotech giant Alexion Pharmaceuticals is in the throes of an internal investigation that saw the abrupt resignations of its CEO and head of finance in December. The issue, which relates to how Alexion marketed its biggest drug, the rare disease treatment Soliris, led the company to delay filing its financial results for the third quarter, further stoking speculation that something particularly bad is afoot. Alexion, based in New Haven, Conn., is widely expected to finally file those quarterly numbers this week, which should illuminate just what’s going on at the multibillion-dollar drug maker.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.